4.7 Article

Multicenter Analysis of Cardiometabolic-related Diagnoses in Transgender and Gender-Diverse Youth: A PEDSnet Study

期刊

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
卷 107, 期 10, 页码 E4004-E4014

出版社

ENDOCRINE SOC
DOI: 10.1210/clinem/dgac469

关键词

gender dysphoria; pediatric; cardiometabolic; cholesterol; body mass index; hormone therapy

资金

  1. National Institutes of Health/National Institute of Child Health and Human Development (National Institutes of Health (NIH)/National Institute of Child Health and Human Development (NICHD)) [K23HD092588, R03HD102773]
  2. National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) [K23HL151868]
  3. Doris Duke Foundation
  4. National Institute of Diabetes and Digestive and Kidney Diseases [T325T32DK063687]
  5. Pediatric Endocrine Society
  6. Society for Adolescent Health and Medicine (A.V.)

向作者/读者索取更多资源

This study using a large database found that transgender and gender-diverse youth have an increased risk of overweight/obesity compared to matched controls. Screening and tailored weight management for TGDY are necessary.
Context Studies on cardiometabolic health in transgender and gender-diverse youth (TGDY) are limited to small cohorts. Objective This work aimed to determine the odds of cardiometabolic-related diagnoses in TGDY compared to matched controls in a cross-sectional analysis, using a large, multisite database (PEDSnet). Methods Electronic health record data (2009-2019) were used to determine odds of cardiometabolic-related outcomes based on diagnosis, anthropometric, and laboratory data using logistic regression among TGDY youth vs controls. The association of gender-affirming hormone therapy (GAHT) with these outcomes was examined separately among TGDY. TGDY (n = 4172) were extracted from 6 PEDSnet sites and propensity-score matched on 8 variables to controls (n = 16 648). Main outcomes measures included odds of having cardiometabolic-related diagnoses among TGDY compared to matched controls, and among TGDY prescribed GAHT compared to those not prescribed GAHT. Results In adjusted analyses, TGDY had higher odds of overweight/obesity (1.2; 95% CI, 1.1-1.3) than controls. TGDY with a testosterone prescription alone or in combination with a gonadotropin-releasing hormone agonist (GnRHa) had higher odds of dyslipidemia (1.7; 95% CI, 1.3-2.3 and 3.7; 95% CI, 2.1-6.7, respectively) and liver dysfunction (1.5; 95% CI, 1.1-1.9 and 2.5; 95% CI, 1.4-4.3) than TGDY not prescribed GAHT. TGDY with a testosterone prescription alone had higher odds of overweight/obesity (1.8; 95% CI, 1.5-2.1) and hypertension (1.6 95% CI, 1.2-2.2) than those not prescribed testosterone. Estradiol and GnRHa alone were not associated with greater odds of cardiometabolic-related diagnoses. Conclusion TGDY have increased odds of overweight/obesity compared to matched controls. Screening and tailored weight management, sensitive to the needs of TGDY, are needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据